- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03923634
Recruitment Status Completed
First Posted April 22, 2019
Last update posted March 2, 2021
Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline visit and at week 3 and 6.
|Experimental: Princess® RICH
Eligible subjects will be injected with Princess® RICH (this is an open-label study). Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids.
Device: Princess® RICH
Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Subjects deemed by the treating physician to have LCL and/or PR of sufficient baseline
severity to merit treatment with Princess® RICH to be corrected
- A negative urine pregnancy test at Visit 1 and commitment to use an adequate method of
birth control for the duration of the clinical investigation (for women of
childbearing potential only.)
- Healthy skin in the facial area and free of diseases that could interfere in cutaneous
- Willingness to abstain from any aesthetic or surgical procedures in the treatment area
for the duration of the clinical investigation
- Written signed and dated informed consent
- Tendency to hypertrophic scars, pigment disorders or keloid formation.
- History of autoimmune disease or receiving therapy for modification of immune response
- Hypersensitivity to hyaluronic acid or glycerol.
- Permanent fillers in the areas to be treated.
- Subjects who are pregnant or breast feeding.
- Subjects who are anticoagulated or with history of bleeding disorder.
- Daily treatment with platelet aggregation inhibitors unless previously cleared by
their primary care physician.
- Cutaneous, inflammatory and/or infectious processes present at V0, recurrent herpes
simplex or (pre) cancerous lesions in the areas to be treated
- Known Diabetes mellitus or uncontrolled systemic diseases in the assessment of the
- Laser therapy, chemical peeling, dermabrasion or botulin toxin treatment in the area
to be treated within less than three months prior to and during the course of the
- Current participation in another clinical investigation
- Subjects whose participation in clinical trials is prohibited by the Austrian Medical
Devices Act (e.g, persons with a legal custodian appointed due to mental disability,
prisoners, soldiers and other members of the armed forces, civil servants)
MaRa-Medical Aesthetic Research Academy
Medizinische Universität-Klinikum für Dermatologie und Venerologie
Principal Investigator: Monika Sulovsky, MD Yuvell
Principal Investigator: Daisy Kopera, MD Medizinische Universität Graz- Klinikum für Dermatologie und Venerologie
Principal Investigator: Thomas Rappl, MD MaRa-Medical Aesthetic Research Academy